相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
P. Leif Bergsagel et al.
BLOOD (2013)
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
G. Bianchi et al.
LEUKEMIA (2013)
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS
J. A. Katzmann et al.
LEUKEMIA (2013)
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
H. Avet-Loiseau et al.
LEUKEMIA (2013)
Exome sequencing in tracking clonal evolution in multiple myeloma following therapy
N. Weston-Bell et al.
LEUKEMIA (2013)
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
J. T. Larsen et al.
LEUKEMIA (2013)
Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?
S. Z. Usmani et al.
LEUKEMIA (2013)
Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease
E. Kastritis et al.
LEUKEMIA (2013)
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2012)
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva et al.
BLOOD (2012)
Have drug combinations supplanted stem cell transplantation in myeloma?
Antonio Palumbo et al.
BLOOD (2012)
CLINICAL TRIALS Consolidation therapy in myeloma: a consolidated approach?
Jesus F. San-Miguel
BLOOD (2012)
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Laura Rosinol et al.
BLOOD (2012)
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
Jan B. Egan et al.
BLOOD (2012)
Clonal competition with alternating dominance in multiple myeloma
Jonathan J. Keats et al.
BLOOD (2012)
Molecular pathogenesis of multiple myeloma and its premalignant precursor
W. Michael Kuehl et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients
B. Paiva et al.
LEUKEMIA (2012)
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
T. Kalina et al.
LEUKEMIA (2012)
Lenalidomide in Myeloma - A High-Maintenance Friend
Ashraf Z. Badros
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
Joaquin Martinez-Lopez et al.
BLOOD (2011)
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
Meletios Dimopoulos et al.
BLOOD (2011)
Can multiple myeloma become a curable disease?
Jesus F. San-Miguel et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Diagnosis of Smoldering Multiple Myeloma
S. Vincent Rajkumar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences
Bart Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma
Jens Hillengass et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping
E. S. Costa et al.
LEUKEMIA (2010)
How I treat multiple myeloma in younger patients
A. Keith Stewart et al.
BLOOD (2009)
The role of complete response in multiple myeloma
Jean-Luc Harousseau et al.
BLOOD (2009)
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
Angela Dispenzieri et al.
BLOOD (2008)
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma
Bart Barlogie et al.
CANCER (2008)
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
Juan Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years
J. Mehta et al.
BONE MARROW TRANSPLANTATION (2007)
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
Ernesto Perez-Persona et al.
BLOOD (2007)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
Fenghuang Zhan et al.
BLOOD (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
SV Rajkumar et al.
BLOOD (2005)
Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
C Cesana et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
A long-term study of prognosis in monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
